American Association for Cancer Research: Investigational Personalized Vaccine Provides Clinical Benefit for Some Patients With Resected Head and Neck Cancers
April 10, 2024
April 10, 2024
SAN DIEGO, California, April 10 (TNSres) -- The American Association for Cancer Research issued the following news release:
TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected HPV-negative head and neck squamous cell cancer (HNSCC), according to results reported at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10.
Patients w . . .
TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected HPV-negative head and neck squamous cell cancer (HNSCC), according to results reported at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10.
Patients w . . .